Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2021-11-16 00:00:00 ET · period of report 2021-11-15 · accession 0001209191-21-064738 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2021-11-16 | 2021-11-15 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale | $187.26 | -3 | 41.1K | -0.0% | -$561.78 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-15 | S | D | 2 | $186.99 | 41,104 | D | — | — | (F2) Open market sales reported on this line occurred at a weighted average price of $186.99 (range $186.67 to $187.31). (F3) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2021-11-15 | S | D | 1 | $187.80 | 41,103 | D | — | — |